lonafarnib has been researched along with Hutchinson Gilford Progeria Syndrome in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.33) | 29.6817 |
| 2010's | 19 (63.33) | 24.3611 |
| 2020's | 10 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Brunsveld, L; Gelb, MH; Hrycyna, CA; Michaelis, S; Tamanoi, F; Van Voorhis, WC; Waldmann, H | 1 |
| Chefo, S; Doan, J; Donohue, K; Jeng, LJB; Joffe, HV; Joseph, DB; Li, RJ; Li, X; Ma, L; Pacanowski, M; Price, D; Shroff, H; Smpokou, P; Suzuki, M; Wang, J; Wang, Y; Yang, Y; Zhang, K; Zhang, X; Zheng, N | 1 |
| Braddock, DT; Gordon, LB; Humphrey, JD; Kawamura, Y; Li, DS; Mikush, N; Murtada, SI; Ramachandra, AB; Ren, P; Tellides, G; Wang, M | 1 |
| Abutaleb, NO; Atchison, L; Bedapudi, A; Cao, K; Choi, L; Gete, Y; Shores, K; Truskey, GA | 1 |
| Djabali, K; Hartinger, R; Lattanzi, G; Lederer, EM; Schena, E | 1 |
| Gordon, LB; Judge, DP; Michaelis, S; Odinammadu, KO; Shilagardi, K; Tuminelli, K | 1 |
| Cabral, WA; Collins, FS; Cubria, MB; DuBose, A; Erdos, MR; Kamalapathy, P; Karim, L; Masoudi, A; Nazarian, A; Oftadeh, R; Snyder, BD; Suarez, S | 1 |
| Aschenbrenner, DS | 1 |
| Dhillon, S | 1 |
| Macicior, J; Marcos-Ramiro, B; Ortega-Gutiérrez, S | 1 |
| Arnold, R; Djabali, K; Randl, H; Vehns, E | 1 |
| Baek, A; Cho, Y; Choi, Y; Kim, D; Kumar, R; Lee, G; Lee, KW; Park, C; Park, SJ; Park, Y; Rampogu, S; Son, M; Zeb, A | 1 |
| Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, JM; Moses, MA | 1 |
| Chicre Bandeira de Melo, P; Grana, AG; Moura Filho, FR; Rodrigues Ferreira Rocha de Alencar, R; Silva, AA | 1 |
| Brazier, J; Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, J; Shappell, H | 1 |
| Jin, ZG; Xu, S | 1 |
| Baltrusaitis, K; Braddock, DT; Cleveland, RH; D'Agostino, RB; Gordon, CM; Gordon, LB; Kieran, MW; Kleinman, ME; Li, X; Liang, MG; Massaro, J; Snyder, B; Walters, M | 1 |
| Bruno, IG; Cooke, JP; Lai, TP; Li, Y; Shay, JW; Sho, S; Tedone, E; Zhang, N; Zhou, G | 1 |
| Jiang, K | 1 |
| Heyer, GL; King, AA | 1 |
| Cho, YJ; Giobbie-Hurder, A; Gordon, LB; Kieran, MW; Kleinman, ME; Miller, DT; Neuberg, D; Silvera, VM; Ullrich, NJ | 1 |
| Brazier, J; Brown, WT; Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, J | 1 |
| Hisama, FM; Martin, GM; Oshima, J | 1 |
| Ghosh, S; Raghunath, M; Sinha, JK | 1 |
| Bancke Laverde, BL; Beirao Junior, PS; Carvalho, VO; Celli, A; Cunico, C; Lucas de Mello, M; Santos Piedade, G | 1 |
| Cleveland, RH; D'Agostino, RB; Dowton, AA; Gerhard-Herman, M; Gordon, CM; Gordon, LB; Greer, MM; Huh, SY; Kieran, MW; Kleinman, ME; Liang, MG; Littlefield, K; Massaro, J; Miller, DT; Nazarian, A; Quinn, N; Shappell, H; Silvera, VM; Smoot, LB; Snyder, BD; Ullrich, NJ | 1 |
| Morse, MA; Wong, NS | 1 |
| Bishop, WR; Cleveland, R; Correia, A; Fligor, B; Gerhard-Herman, M; Giobbie-Hurder, A; Gordon, CM; Gordon, LB; Huh, SY; Kieran, MW; Kleinman, ME; Liang, MG; Miller, DT; Nazarian, A; Neuberg, DS; Ploski, C; Quinn, N; Regen, A; Riley, S; Schwartzman, A; Smoot, LB; Snyder, BD; Sonis, A; Statkevich, P; Ullrich, NJ | 1 |
| Couzin-Frankel, J | 1 |
| Wadman, M | 1 |
6 review(s) available for lonafarnib and Hutchinson Gilford Progeria Syndrome
| Article | Year |
|---|---|
Therapeutic intervention based on protein prenylation and associated modifications.
Topics: Animals; Antineoplastic Agents; Humans; Models, Molecular; Molecular Conformation; Progeria; Protein Prenylation; Proteins | 2006 |
Lonafarnib: First Approval.
Topics: Antiviral Agents; Enzyme Inhibitors; Farnesyltranstransferase; Hepatitis D; Humans; Piperidines; Progeria; Pyridines | 2021 |
Small-Molecule Therapeutic Perspectives for the Treatment of Progeria.
Topics: Aging; Aging, Premature; Cell Nucleus; Cellular Senescence; Fibroblasts; Humans; Lamin Type A; Laminopathies; Mutation; Nuclear Lamina; Phenotype; Piperidines; Progeria; Pyridines; Skin; Small Molecule Libraries | 2021 |
Hutchinson-Gilford Progeria Syndrome: Cardiovascular Pathologies and Potential Therapies.
Topics: Cardiovascular Diseases; Humans; Piperidines; Progeria; Pyridines | 2019 |
Progeria: a rare genetic premature ageing disorder.
Topics: Aging; Child; Clinical Trials as Topic; Humans; Lamin Type A; Longevity; Mutation; Piperidines; Prenylation; Progeria; Pyridines; Rare Diseases | 2014 |
Lonafarnib for cancer and progeria.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Piperidines; Progeria; Protein Prenylation; Pyridines; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
3 trial(s) available for lonafarnib and Hutchinson Gilford Progeria Syndrome
| Article | Year |
|---|---|
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Male; Nervous System Diseases; Piperidines; Progeria; Pyridines; Retrospective Studies; Treatment Outcome | 2013 |
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
Topics: Bone and Bones; Carotid Arteries; Child, Preschool; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Infant; Male; Piperidines; Pravastatin; Progeria; Prospective Studies; Protein Prenylation; Pyridines; Zoledronic Acid | 2016 |
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
Topics: Adolescent; Carotid Arteries; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Piperidines; Progeria; Pulse Wave Analysis; Pyridines; Treatment Outcome; Vomiting; Weight Gain | 2012 |
21 other study(ies) available for lonafarnib and Hutchinson Gilford Progeria Syndrome
| Article | Year |
|---|---|
FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
Topics: Humans; Lamin Type A; Piperidines; Progeria; Pyridines; United States | 2023 |
Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome.
Topics: Animals; Lamin Type A; Mice; Piperidines; Progeria; Pulse Wave Analysis; Sirolimus | 2023 |
Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome.
Topics: Atherosclerosis; Calcinosis; Endothelial Cells; Everolimus; Humans; Induced Pluripotent Stem Cells; Lamin Type A; Progeria | 2023 |
Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson-Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies.
Topics: Adipogenesis; Humans; Lipodystrophy; Mutation; Progeria | 2023 |
The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Topics: Child; Enzyme Inhibitors; Fibroblasts; Humans; Lamin Type A; Lipodystrophy; Membrane Proteins; Metalloendopeptidases; Mutation; Progeria; Transferases | 2023 |
Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
Topics: Aging; Animals; Bone and Bones; Bone Density Conservation Agents; Cartilage; Disease Models, Animal; Femur; Glycosaminoglycans; Joints; Lamin Type A; Mice; Mice, Transgenic; Mutation; Osteoarthritis; Phenotype; Piperidines; Pravastatin; Progeria; Protein Processing, Post-Translational; Pyridines; X-Ray Microtomography; Zoledronic Acid | 2020 |
New Drugs for Rare Disorders.
Topics: alpha-MSH; Anti-Obesity Agents; Humans; Piperidines; Progeria; Pyridines; Rare Diseases | 2021 |
Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
Topics: Adolescent; Azetidines; Cells, Cultured; Child, Preschool; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Male; Piperidines; Progeria; Purines; Pyrazoles; Pyridines; STAT1 Transcription Factor; Sulfonamides | 2021 |
Computational Exploration for Lead Compounds That Can Reverse the Nuclear Morphology in Progeria.
Topics: Drug Design; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Progeria; Pyridines | 2017 |
Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib.
Topics: Adolescent; beta 2-Microglobulin; Biomarkers; Blood Proteins; C-Reactive Protein; Case-Control Studies; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Interleukin-13; Interleukin-1alpha; Interleukin-7; Lamin Type A; Longitudinal Studies; Male; Mutation; Myoglobin; Piperidines; Progeria; Prospective Studies; Pyridines | 2018 |
Progeria: case report and new drugs perspectives.
Topics: Cell Nucleus; Child, Preschool; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lamin Type A; Mutation; Piperidines; Progeria; Pyridines | 2018 |
Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
Topics: Adolescent; Adult; Cause of Death; Child; Cohort Studies; Enzyme Inhibitors; Female; Humans; Kaplan-Meier Estimate; Lamin Type A; Male; Phosphotransferases (Phosphate Group Acceptor); Piperidines; Progeria; Protein Processing, Post-Translational; Pyridines; Young Adult | 2018 |
Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
Topics: Calcinosis; Calcium; Child; Child, Preschool; Creatinine; Female; Fibroblast Growth Factor-23; Humans; In Vitro Techniques; Lamin Type A; Male; Parathyroid Hormone; Piperidines; Pravastatin; Progeria; Pyridines; Zoledronic Acid | 2019 |
Transient introduction of human telomerase mRNA improves hallmarks of progeria cells.
Topics: Adolescent; Adult; Aged; Cell Line; Cellular Senescence; Child; Child, Preschool; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fibroblasts; Humans; Infant; Infant, Newborn; Lamin Type A; Male; Piperidines; Progeria; Pyridines; RNA, Messenger; Telomerase; Telomere; Telomere Homeostasis; Transfection | 2019 |
Drug development for progeria yields insights into normal aging.
Topics: Aging; Child; Clinical Trials as Topic; Diphosphonates; Drug Discovery; Humans; Imidazoles; Lamin Type A; Mutation; Piperidines; Pravastatin; Progeria; Pyridines; Time Factors; Zoledronic Acid | 2013 |
Moving from gene discovery to clinical trials in Hutchinson-Gilford progeria syndrome.
Topics: Female; Humans; Male; Nervous System Diseases; Piperidines; Progeria; Pyridines | 2013 |
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Topics: Adolescent; Adult; Alkyl and Aryl Transferases; Atherosclerosis; Cause of Death; Child; Child, Preschool; Clinical Trials as Topic; Cohort Studies; Dimethylallyltranstransferase; Diphosphonates; Drug Therapy, Combination; Female; Genes, Dominant; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Kaplan-Meier Estimate; Lamin Type A; Male; Multicenter Studies as Topic; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Proportional Hazards Models; Protein Precursors; Protein Prenylation; Pyridines; Treatment Outcome; Young Adult; Zoledronic Acid | 2014 |
An encouraging progress report on the treatment of progeria and its implications for atherogenesis.
Topics: Diphosphonates; Female; Humans; Imidazoles; Lamin Type A; Male; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Protein Precursors; Protein Prenylation; Pyridines; Zoledronic Acid | 2014 |
Progeria and the early aging in children: a case report.
Topics: Aging; Body Height; Body Weight; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Infant; Lamin Type A; Piperidines; Progeria; Pyridines | 2016 |
Medicine. Drug trial offers uncertain start in race to save children with progeria.
Topics: Animals; Child, Preschool; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Foundations; Humans; Lamin Type A; Mice; Mutation; Patient Selection; Piperidines; Progeria; Pyridines; Uncertainty; United States; United States Public Health Service | 2012 |
New cures sought from old drugs.
Topics: Child; Crowdsourcing; Drug Repositioning; Humans; National Institutes of Health (U.S.); Piperidines; Progeria; Pyridines; United States | 2012 |